Literature DB >> 26852905

Neural substrates of the 'low-level' system for speech articulation: Evidence from primary opercular syndrome.

Maria Caterina Silveri1, Francesco Incordino2, Rita Lo Monaco2, Alessandra Bizzarro3, Carlo Masullo3, Francesca Piludu4, Cesare Colosimo5.   

Abstract

We describe a patient with progressive disorder of speech, without language impairment (opercular syndrome). Morphometric analysis confirmed asymmetric volume reduction of the precentral areas (>left). Diffusion imaging showed significant white matter changes in the left frontal lobe, with specific involvement of the left corticobulbar tract and connections between supplementary/pre-supplementary motor areas and the frontal operculum (frontal aslant tract). We suggest that the organization of expressive language includes a 'low level' motor system principally distributed in the left hemisphere that shows specific susceptibility to neurodegeneration, distinct from neural systems subtending praxic, and cognitive aspects of language.
© 2016 The British Psychological Society.

Entities:  

Keywords:  aslant tract; opercular syndrome; phonological short-term memory; primary anarthria

Mesh:

Year:  2016        PMID: 26852905     DOI: 10.1111/jnp.12099

Source DB:  PubMed          Journal:  J Neuropsychol        ISSN: 1748-6645            Impact factor:   2.864


  2 in total

1.  Atypical Callosal Morphology in Children with Speech Sound Disorder.

Authors:  Eileen Luders; Florian Kurth; Lauren Pigdon; Gina Conti-Ramsden; Sheena Reilly; Angela T Morgan
Journal:  Neuroscience       Date:  2017-11-02       Impact factor: 3.590

2.  The Frontal Aslant Tract: A Systematic Review for Neurosurgical Applications.

Authors:  Emanuele La Corte; Daniela Eldahaby; Elena Greco; Domenico Aquino; Giacomo Bertolini; Vincenzo Levi; Malte Ottenhausen; Greta Demichelis; Luigi Michele Romito; Francesco Acerbi; Morgan Broggi; Marco Paolo Schiariti; Paolo Ferroli; Maria Grazia Bruzzone; Graziano Serrao
Journal:  Front Neurol       Date:  2021-02-24       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.